GHAPPcast: Simplifying Access: Evolving Drug Distribution Channels
GHAPPcast25 Maalis 2025

GHAPPcast: Simplifying Access: Evolving Drug Distribution Channels

In the final installment of our Simplified Access Series, we turn our focus to the evolving drug distribution landscape, including specialty pharmacy dynamics, hospital-based models, and the increasing influence of white bagging, brown bagging, and payer mandates.

Join host Allison Moser, NP, with returning guests Tedra Gray, NP, and Jeff Dunn, PharmD (President of a transparent PBM), as they explore how these shifts are impacting real-world patient access and clinical workflow.

In this episode, we break down the rising use of limited distribution drugs, strategies for navigating specialty pharmacy restrictions, and how clinicians are adapting to maintain timely access to infusion therapies. Allison and Tedra share how close collaboration with hospital-based specialty pharmacists is helping to overcome administrative and logistical hurdles, while Jeff offers an industry view on why payers are pushing toward pharmacy benefit distribution and the cost pressures behind it.

We also explore the disconnect between payers and hospitals in negotiating drug costs, and how silos in coverage, formularies, and rebates may be contributing to access barriers. The episode wraps with a forward-looking conversation on shared risk models, value-based care, and the need for stronger collaboration across healthcare stakeholders to build a more sustainable and equitable system.

To catch up on the full series, watch Episodes 1 and 2 on the GHAPP digital hub.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(155)

FAQ: QUASAR Long Term Extension Interim Analysis

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Kesä 4min

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Touko 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Touko 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Touko 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Touko 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Touko 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Huhti 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Huhti 23min

Suosittua kategoriassa Terveys ja hyvinvointi

unicast
rss-pitaisko-erota
psykopodiaa-podcast
vakeva-elama-viisaampi-mieli-vahvempi-keho
tiedenaiset-podcast
voi-hyvin-meditaatiot-2
puhu-muru
rss-kuumilla-aalloilla
rss-pt-paahtio
rss-narsisti
meditaatiot-suomeksi
terapiassa
rss-uplevel-by-sonja-hannus
katilon-kahvitunti
fitnessvastaanotto
paritellen
rss-nautinto
rss-terapiaklubi
junnut-pelissa
monisuhteellista